Duncan Jodrell publications

Optimization of the Antitumor Activity of Sequence-specific Pyrrolobenzodiazepine Derivatives Based on their Affinity for ABC Transporters
Kaliszczak M;Antonow D;Patel KI;Howard P;Jodrell DI;Thurston DE;Guichard SM
AAPS J 2010; 12 (4 ):617-627.
UKPubMed (open access);  PubMed;  DOI: 10.1208/s12248-010-9225-x.

Structure-Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents
Antonow D;Kaliszczak M;Kang GD;Coffils M;Tiberghien AC;Cooper N;Barata T;Heidelberger S;James CH;Zloh M;Jenkins TC;Reszka AP;Neidle S;Guichard SM;Jodrell DI;Hartley JA;Howard PW;Thurston DE
J Med Chem 2010; 53 (7):2927-2941.
PubMed;  DOI: 10.1021/jm901722v.

Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro
Connolly K;Mitter R;Muir M;Jodrell D;Guichard S
Cancer Chemother Pharmacol 2009; 64 (2):307-316.
PubMed;  DOI: 10.1007/s00280-008-0872-x.

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer
Dean E;Jodrell D;Connolly K;Danson S;Jolivet J;Durkin J;Morris S;Jowle D;Ward T;Cummings J;Dickinson G;Aarons L;LaCasse E;Robson L;Dive C;Ranson M
J Clin Oncol 2009; 27 (10):1660-1666.
PubMed;  DOI: 10.1200/JCO.2008.19.5677.

ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136
Aird RE;Thomson M;Macpherson JS;Thurston DE;Jodrell DI;Guichard SM
Pharmacogenomics J 2008; 8 (4):289-296.

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer
Brown ER;Charles KA;Hoare SA;Rye RL;Jodrell DI;Aird RE;Vora R;Prabhakar U;Nakada M;Corringham RE;DeWitte M;Sturgeon C;Propper D;Balkwill FR;Smyth JF
Ann Oncol 2008; 19 (7):1340-1346.

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors
Izquierdo MA;Bowman A;Garcia M;Jodrell D;Martinez M;Pardo B;Gomez J;Lopez-Martin JA;Jimeno J;Germa JR;Smyth JF
Clin Cancer Res 2008; 14 (10):3105-3112.

Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies
Patel K;Guichard SM;Jodrell DI
J Chromatogr B Analyt Technol Biomed Life Sci 2008; 863 (1):19-25.

Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity
Guichard SM;Macpherson JS;Mayer I;Reid E;Muir M;Dodds M;Alexander S;Jodrell DI
Eur J Cancer 2008; 44 (2):310-317.
PubMed;  DOI: 10.1016/j.ejca.2007.10.023.

Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model
Guichard SM;Hua ML;Kang P;Macpherson JS;Jodrell DI
Cancer Chemother Pharmacol 2007; 60 (5):651-660.

Aspirin activates the NF-kappa B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer
Stark LA;Reid K;Sansom OJ;Din FV;Guichard S;Mayer I;Jodrell DI;Clarke AR;Dunlop MG
Carcinogenesis 2007; 28 (5):968-976.

Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands
Habtemariam A;Melchart M;Fernandez R;Parsons S;Oswald IDH;Parkin A;Fabbiani FPA;Davidson JE;Dawson A;Aird RE;Jodrell DI;Sadler PJ
J Med Chem 2006; 49 (23):6858-6868.

Time-dependent cytotoxicity induced by SJU-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling
Arnould S;Spanswick VJ;Macpherson JS;Hartley JA;Thurston DE;Jodrell DI;Guichard SM
Mol Cancer Ther 2006; 5 (6):1602-1609.

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds
Guichard SM;Else R;Reid E;Zeitlin B;Aird R;Muir M;Dodds M;Fiebig H;Sadler PJ;Jodrell DI
Biochem Pharmacol 2006; 71 (4):408-415.

Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer
Chau I;Norman AR;Cunningham D;Iveson T;Hill M;Hickish T;Lofts F;Jodrell D;Webb A;Tait D;Ross PJ;Shellito P;Oates JR
Eur J Cancer 2005; 41 (11):1551-1559.

ER beta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates
Wong NACS;Malcomson RDG;Jodrell DI;Groome NP;Harrison DJ;Saunders PTK
J Pathol 2005; 207 (1):53-60.

Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity
Wang FY;Habtemariam A;van der Geer EPL;Fernandez R;Melchart M;Deeth RJ;Aird R;Guichard S;Fabbiani FPA;Lozano-Casal P;Oswald IDH;Jodrell DI;Parsons S;Sadler PJ
Proc Natl Acad Sci U S A 2005; 102 (51):18269-18274.

Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies
Guichard SM;Mayer I;Jodrell DI
J Chromatogr B Analyt Technol Biomed Life Sci 2005; 826 (1-2):232-237.

Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136
Guichard SM;Macpherson JS;Thurston DE;Jodrell DI
Eur J Cancer 2005; 41 (12):1811-1818.

The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines
Sewell JM;Mayer I;Langdon SP;Smyth JF;Jodrell DI;Guichard SM
Eur J Cancer 2005; 41 (11):1637-1644.

Capecitabine as adjuvant treatment for stage III colon cancer
Twelves C;Wong A;Nowacki MP;Abt M;Burris H;Carrato A;Cassidy J;Cervantes A;Fagerberg J;Georgoulias V;Husseini F;Jodrell D;Koralewski P;Kroning H;Maroun J;Marschner N;McKendrick J;Pawlicki M;Rosso R;Schuller J;Seitz JF;Stabuc B;Tujakowski J;Van Hazel G;Zaluski J;Scheithauer W
N Engl J Med 2005; 352 (26):2696-2704.

Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer
Camidge R;Reigner B;Cassidy J;Grange S;Abt M;Weidekamm E;Jodrell D
J Clin Oncol 2005; 23 (21):4719-4725.

Prognosis without treatment as a modifier in health economic assessments
Camidge R;Walker A;Oliver JJ;Nussey F;Maxwell S;Jodrell D;Webb DJ
BMJ 2005; 330 (7504):1382-1384.

Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175
Hayward RL;Schornagel QC;Tente R;Macpherson JC;Aird RE;Guichard S;Habtemariam A;Sadler P;Jodrell DI
Cancer Chemother Pharmacol 2005; 55 (6):577-583.

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer
Chau I;Norman AR;Cunningham D;Tait D;Ross PJ;Iveson T;Hill M;Hickish T;Lofts F;Jodrell D;Webb A;Oates JR
Ann Oncol 2005; 16 (4):549-557.

Expression of V-1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition
MacKinnon AC;Tufail-Hanif U;Lucas CD;Jodrell D;Haslett C;Sethi T
Br J Cancer 2005; 92 (3):522-531.

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesopliageal adenocarcinoma
Jodrell DI;Evans TRJ;Steward W;Cameron D;Prendiville J;Aschele C;Noberasco C;Lind M;Carmichael J;Dobbs N;Camboni G;Gatti B;De Braud F
Eur J Cancer 2004; 40 (12):1872-1877.

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.
Wall L;Talbot DC;Bradbury P;Jodrell DI
Br J Cancer 2004; 90 (4):800-804.

Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect.
Hayward RL;Macpherson JS;Cummings J;Monia BP;Smyth JF;Jodrell DI
Mol Cancer Ther 2004; 3 (2):169-178.

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Gourley C;Cassidy J;Edwards C;Samuel L;Bisset D;Camboni G;Young A;Boyle D;Jodrell D
Cancer Chemother Pharmacol 2004; 53 (2):95-101.

Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Cummings J;Zelcer N;Allen JD;Yao DG;Boyd G;Maliepaard M;Friedberg TH;Smyth JF;Jodrell DI
Biochem Pharmacol 2004; 67 (1):31-39.

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
Saini A;Norman AR;Cunningham D;Chau I;Hill M;Tait D;Hickish T;Iveson T;Lofts F;Jodrell D;Ross PJ;Oates J
Br J Cancer 2003; 88 (12):1859-1865.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
Scheithauer W;McKendrick J;Begbie S;Borner M;Burns WI;Burris HA;Cassidy J;Jodrell D;Koralewski P;Levine EL;Marschner N;Maroun J;Garcia-Alfonso P;Tujakowski J;Van Hazel G;Wong A;Zaluski J;Twelves C;X-ACT Study Group
Ann Oncol 2003; 14 (12):1735-1743.

Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Cummings J;Ethell BT;Jardine L;Boyd G;Macpherson JS;Burchell B;Smyth JF;Jodrell DI
Cancer Res 2003; 63 (23):8443-8450.

Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL;Macpherson JS;Cummings J;Monia BP;Smyth JF;Jodrell DI
Clin Cancer Res 2003; 9 (7):2856-2865.

Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg(6),D-Trp7,9,N(me)Phe(8)]-substance P (6-11)-induced growth inhibition
Waters CM;MacKinnon AC;Cummings J;Tufail-Hanif U;Jodrell D;Haslett C;Sethi T
Br J Cancer 2003; 88 (11):1808-1816.

Efficacy, safety, and cost of new anticancer drugs: pessimistic conclusion was not justified.
Calvert H;Jodrell DI;Cassidy J;Harris AL
BMJ 2002; 325 (7375):1302-1303.

Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography.
Cummings J;Ethell BT;Boyd G;Burchell B;Smyth JF;Jodrell DI
Chromatographia 2002; 55 (Suppl):S157-S163.

Factors influencing the cellular accumulation of SN-38 and camptothecin.
Cummings J;Boyd G;Macpherson JS;Wolf H;Smith G;Smyth JF;Jodrell DI
Cancer Chemother Pharmacol 2002; 49 (3):194-200.

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Cummings J;Boyd G;Ethell BT;Macpherson JS;Burchell B;Smyth JF;Jodrell DI
Biochem Pharmacol 2002; 63 (4):607-613.

Cyclin DI overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation.
Wong NACS;Morris RG;McCondochie A;Bader S;Jodrell DI;Harrison DJ
J Pathol 2002; 197 (1):128-135.